Molecular targeted therapy for advanced hepatocellular carcinoma

Targeted Oncology

Volumn 2, Issue 4, 2007, Pages 199-210

  Shen, Ying Chun ^a   Hsu, Chiun ^a   Cheng, Ann Lii ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Hepatocellular carcinoma; Molecular targeted therapy

Indexed keywords

EID: 35748947721     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-007-0058-1     Document Type: Article

References (150)

1. Jemal A, Murray T, Ward E et al (2005) Cancer Statistics 2005. CA Cancer J Clin 55:10-30
2. Marrero JA (2005) Hepatocellular carcinoma. Curr Opin Gastroenterol 21:308-312
3. Chang MH, Chen CJ, Lai MS et al (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336:1855-1859
4. Lee CL, Hsieh KS, Ko YC (2003) Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination. Cancer Epidemiol Biomarkers Prev 12:57-59
5. Williams R (2006) Global changes on liver diseases. Hepatology 44:521-526
6. Perz JF, Armstrong GL, Farrington LA et al (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529-538
7. Nagasue N, Kohno H, Chang YC et al (1993) Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 217: 375-385
8. Yanaga K (2004) Current status of hepatic resection for hepatocellular carcinoma. J Gastroenterol 39:919-926
9. Hsu C, Cheng JC, Cheng AL (2004) Recent advances in non-surgical treatment for advanced hepatocellular carcinoma (HCC). J Formos Med Assoc 103:483-495
10. Zhu AX (2006) Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11:790-800
11. Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4:361-370
12. Sridhar R, Hanson-Painton O, Cooper DR (2000) Protein kinases as therapeutic targets. Pharm Res 17:1345-1353
13. Nobel ME, Endicott JA, Johnson, LN (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303:1800-1805
14. Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Eng J Med 344:1031-1037
15. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246
16. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
17. Koh JS, Trent J, Chen L et al (2004) Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate. Histol Histopathol 19:565-574
18. Saltz LB, Meropol NJ, Loehrer PJ Sr et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208
19. Druker BJ, Guihot F, O'Brien SG et al (2006) Five-year follow-up of receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417
20. Yang JC (2004) Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 10:6367S-6370S
21. Hainsworth JD, Sosman JA, Raefsky EL et al (2005) Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23:7889-7896
22. Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24
23. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
24. Thomas MB, Abbruzzese JL (2005) Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 23:8093-8108
25. Avila MA, Berasain C, Sangro B et al (2006) New therapies for hepatocellular carcinoma. Oncogene 25:3866-3884
26. Breuhahn K, Longerich T, Schirmacher P (2006) Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25:3787-3800
27. Ito Y, Sasaki Y, Horimoto M et al (1998) Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27:951-958
28. Huynh H, Nguyen TT, Chow KH et al (2003) Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 8:3-19
29. Lee HC, Tian B, Sedivy JM et al (2006) Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 131:1208-1217
30. Erhardt A, Hassan M, Heintges T et al (2002) Hepatitis C virus core protein induces cell proliferation and activates ERK, JNK, and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-Off cell line. Virology 292:272-284
31. Chung TW, Lee YC, Kim CH (2004) Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J 18:1123-1125
32. Bataller R, Paik YH, Lindquist JN et al (2004) Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 126:529-540
33. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
34. Kane RC, Farrell AT, Saber H et al (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12:7271-7278
35. Abou-Alfa GK, Schwartz L, Ricci S et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300
36. Llovet J, Ricci S, Mazzaferro V et al (2007) Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). Pro Am Soc Clin Oncol late-breaking abstract 1
37. Yamaguchi R, Yano H, Iemura A et al (1998) Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28:68-77
38. Mise M, Arii S, Higashituji H et al (1996) Clinical significance of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hepatology 23:455-464
39. Chow NH, Hsu PI, Lin XZ et al (1997) Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 28:698-703
40. Park YN, Kim YB, Yang KM et al (2000) Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep heaptocarcinogenesis. Arch Pathol Lab Med 124:1061-1065
41. Li Q, Xu B, Fu L et al (2006) Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma. J Exp Clin Cancer Res 25:403-409
42. El-Assal ON, Yamanoi A, Ono T et al (2001) The clinicopathological significance of heparanase and basic fibroblast growth factor expression in hepatocellular carcinoma. Clin Cancer Res 7:1299-1305
43. Poon RT, Hg IO, Lau C et al (2001) Correlation of serum basic fibroblast growth factor levels with clinicopathological features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 182:298-234
44. Tsou AP, Wu KM, Tsen TY et al (1998) Parallel hybridization analysis of multiple protein kinase. Genomics 50:331-340
45. Tanaka S, Mori M, Sakamoto Y et al (1999) Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103:341-345
46. Mitsuhashi N, Shimizu H, Ohtsuka M et al (2003) Angiopoietin and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 37:1105-1113
47. Harada T, Arii S, Mise M et al (1998) Membrane-type matrix metalloproteinase-1 (MT1-MMP) gene is overexpressed in highly invasive hepatocellular carcinomas. J Hepatol 28:231-239
48. Ogasawara S, Yano H, Momosaki S et al (2005) Expression of matrix metalloproteinases (MMPs) in cultured hepatocellular carcinoma (HCC) cells and surgically resected HCC tissues. Oncol Rep 13:1043-1048
49. Suzuki K, Hayashi N, Miyamoto Y et al (1996) Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 56:3004-3009
50. Mise M, Arii S, Higashituji H et al (1996) Clinical significance of vascular endothelial growth factor and basic fibroblast growth facto gene expression in liver tumor. Hepatology 23:455-464
51. Li XM, Tang ZY, Zhou G et al (1998) Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer 17:13-17
52. Tshii Y, Nakasato Y, Kobayashi S et al (2003) A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma. J Exp Clin Cancer Res 22:461-470
53. Jiang YF, Yang ZH, Hu JQ (2000) Recurrence or metastasis of HCC: predictors, early detection and experimental antiangiogenic therapy. World J Gastroenterol 6:61-65
54. Dhar DK, Ono T, Yamanoi A et al (2002) Serum endostatin predicts tumor vascularity in hepatocellular carcinoma. Cancer 95:2188-2195
55. D'Amato RJ, Loughnan MS, Flynn E et al (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085
56. Kruse FE, Joussen AM, Rohrschneider K et al (1998) Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Opthalmol 236:461-466
57. Kumar S, Witzig TE, Dispenzieri A et al (2004) Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 18:624-627
58. Fine HA, Figg WD, Jaeckle K et al (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708-715
59. Little RF, Wyvill KM, Pluda JM et al (2000) Activity of thalidomide in AIDS-related Kaposi sarcoma. J Clin Oncol 18:2593-2602
60. Hsu C, Chen CN, Chen LT et al (2003) Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 65:242-249
61. Patt YZ, Hassan MM, Lozano RD et al (2005) Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 103:749-755
62. Lin AY, Brophy N, Fisher GA et al (2005) Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 103:119-125
63. Chiou HE, Wang TE, Wang YY et al (2006) Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World J Gastroenterol 12:6955-6960
64. Hsu C, Chen CN, Chen LT et al (2005) Effect of thalidomide in hepatocellular carcinoma: assessment with power Doppler US and analysis of circulating angiogenic factors. Radiology 235:509-516
65. Wang J, Chen LT, Tsang YM et al (2004) Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR Am J Roentgenol 183:713-719
66. Hussein MA (2006) Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 95:924-930
67. Ho CH (1997) Prevalence of activated protein C resistance in the Chinese population. Thromb Res 88:409-412
68. Ng IO, Poon RT, Lee JM et al (2001) Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 116:838-845
69. Liu Y, Poon RT, Li Q et al (2005) Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 65:3691-3699
70. Schwartz JD, Schwartz M, Lehrer D et al (2005) Bevacizumab in hepatocellular carcinoma (HCC) in patients without metastasis and without invasion of the portal vein. Pro Am Soc Clin Oncol: abstract 4122
71. Schwartz JD, Schwartz M, Lehrer D et al (2006) Bevacizumab in hepatocellular carcinoma in patients without invasion of the portal vein. Pro Am Soc Clin Oncol: abstract 4144
72. Kabbinavar F, Hurwitz H, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leocovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65
73. Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 22:2184-2191
74. Goodman VL, Rock EP, Dagher R et al (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13:1367-1373
75. Faivre SJ, Raymond E, Douillard J et al (2007) Assessment of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma (HCC). Pro Am Soc Clin Oncol: abstract 3546
76. Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33:369-385
77. Ono M, Morisawa K, Nie J (1998) Transactivation of transforming growth factor alpha gene by hepatitis B virus preS1. Cancer Res 58:1813-1816
78. Sato Y, Kato J, Takimoto R et al (2006) Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB. Gut 55:1801-1808
79. Jakubczak JL, Chisari FV, Merlino G (1997) Synergy between transforming growth factor alpha and hepatitis B virus surface antigen in hepatocellular proliferation and carcinogenesis. Cancer Res 57:3606-3611
80. Hopfner M, Sutter AP, Huether A et al (2004) Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 41:1008-1016
81. Huether A, Hopfner M, Sutter AP et al (2005) Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 43:661-669
82. Kiss A, Wang NJ, Xie JP et al (1997) Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met, TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 3:1059-1066
83. Hsu C, Huang CL, Hsu HC et al (2002) HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity. Cancer 94:415-420
84. Su MC, Lien HC, Jeng YM (2005) Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcioma. Cancer Lett 224:117-121
85. Philip PA, Mahoney MR, Allmer C et al (2005) Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657-6663
86. Thomas MB, Ghadha R, Glover K et al (2007) Phase II study of erlotinib on patients with unresectable hepatocellular carcinoma. Cancer (in press)
87. Ramanathan RK, Belani CP, Singh DA et al (2006) Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. Pro Am Soc Clin Oncol: abstract 4010
88. Vergote IB, Y Humblet, van Cutsem E et al (2005) A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: interim data. Proc Am Soc Clin Oncol: abstract 3162
89. O'Dwyer PJ, Gianotonio BJ, Levy DE et al (2006) Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203. Proc Am Soc Clin Oncol: abstract 4143
90. Gruenwald V, Wilkens L, Gebel M et al (2006) A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma. Pro Am Soc Clin Oncol: abstract 14079
91. Zhu AX, Stuart K, Blaszkowsky LS et al (2007) Phase 2 study of cetuximab in patients with advanced HCC. Cancer 110:581-589
92. Darin M, Cao Y, Greten FR et al (2002) NF-kappa B in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301-310
93. Arsura M, Cavin LG (2005) Nuclear factor-kappa B and liver carcinogenesis. Cancer Lett 229:157-169
94. Diao J, Garces R, Richardson CD (2001) X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis. Cytokine Growth Factor Rev 12:189-205
95. Kato N, Yoshida H, Kioko Ono-Nita S et al (2000) Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 32:405-412
96. Tai DI, Tsai SL, Chen YM et al (2000) Activation of nuclear factor kappa B in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology 31:656-664
97. Tai DI, Tsai SL, Chang YH et al (2000) Constitutive activation of nuclear factor kappa B in hepatocellular carcinoma. Cancer 89:2274-2281
98. Chan CF, Yau TO, Jin DY et al (2004) Evaluation of nuclear factor-kappa B, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res 10:4140-4149
99. Karin M, Yamamoto Y, Wang QM (2004) The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Dis 3:17-26
100. Richardson PG, Barlogie B, Berenson J, et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617
101. Chen KF, Yu CH, Chen PJ et al (2006) The inhibition of PI3K/Akt pathway as a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Eur J Cancer 4:148
102. Chiao PJ, Na R, Niu J et al (2002) Role of Rel/NF-κB transcription factors in apoptosis of human hepatocellular carcinoma cells. Cancer 95:1696-1705
103. Hegewisch-Becker S, Sterneck M, Schubert U et al (2004) Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC). Pro Am Soc Clin Oncol: abstract 4089
104. Olivier S, Robe P, Bours V (2006) Can NF-kappaB be a target for novel and efficient anti-cancer agents? Biochem Pharmacol 72:1054-1068
105. Chuang SE, Kuo ML, Hsu CH et al (2000) Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis 21:331-335
106. Kern MA, Schubert D, Sahi D et al (2002) Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 36:885-894
107. Yu J, Qiao L, Zimmermann L et al (2006) Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 43:134-143
108. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335-348
109. Vignot S, Faivre S, Aguirre D et al (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:525-537
110. Easton JB, Houghton PJ (2006) mTOR and cancer therapy. Oncogene 25:6436-6446
111. Sahin F, Kannangai R, Adegbola O et al (2004) mTOR and P70S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10:8421-8425
112. Fujiwara Y, Hoon DS, Yamada T et al (2000) PTEN/MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinoma. Jpn J Cancer Res 92:287-292
113. Hu TH, Huang CC, Lin PR et al (2003) Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 97:1929-1940
114. Rizell M, Cahlin C, Olausson M et al (2006) mTOR inhibition affects primary liver cancer. Pro Am Soc Clin Oncol: abstract 14106
115. Carmena M, Earnshaw MC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4:842-854
116. Jeng YM, Peng SY, Lin CY et al (2004) Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10:2065-2071
117. Keen N, Taylor S (2004) Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4:927-936
118. Schellens JH, Boss D, Witteveen PO et al (2006) Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. Pro Am Soc Clin Oncol: abstract 3008
119. Giles F, Cortes J, Bergstrom DA et al (2006) MK-0457, a novel multikinase inhibitor, is active in patients with chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL) with the T315I BCR-ABL resistance mutation and patients with refractory JAK-2 positive myeloproliferative diseases (MPD). Blood 108: abstract 253
120. Lin ZZ, Hsu CH, Hsu C et al (2006) VE-465, a novel small-molecule inhibitor of the Aurora kinases, shows anticancer effects in human hepatocellular carcinoma. Proc Am Assoc Cancer Res: abstract LB 279
121. Tornillo L, Terracciano LM (2006) An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 59:557-563
122. Lee ES, Han EM, Kim YS et al (2005) Occurrence of c-Kit+ tumor cells in hepatitis B virus-associated hepatocellular carcinoma. Am J Clin Pathol 124:31-36
123. Potti A, Ganti AK, Tendulkar K et al (2003) Her-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. Anticancer Res 23:2671-2674
124. Chung CY, Yeh KT, Hsu NC et al (2005) Expression of c-kit protooncogene in human hepatocellular carcinoma. Cancer Lett 217:231-236
125. Savage DG, Antman KH (2003) Imatinib mesylate-a new oral targeted therapy. N Engl J Med 346:683-694
126. Armbrust T, Baumhoer D, Werner J et al (2005) Treatment of hepatocellular carcinoma (HCC) with the tyrosine kinase inhibitor imatinib. Pro Am Soc Clin Oncol: abstract 4210
127. Lin AY, Fisher G, So S et al (2005) A phase II study of imatinib mesylate (IM) in patients (pts) with unresectable hepatocellular carcinoma (HCC). Pro Am Soc Clin Oncol: abstract 4223
128. Eckel F, von Delius S, Dobritz M et al (2005) Pharmacokinetic (PK) and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma (HCC). Oncology 69:363-371
129. Thomas MB, Chadha R, Iwasaki M et al (2007) The combination of bevacizumab (B) and erlotinib (E) shows significant biologic activity in patients with advanced hepatocellular carcinoma (HCC). Pro Am Soc Clin Oncol: abstract 4567
130. Kabbinavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697-3705
131. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508
132. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
133. Zhu AX, Blaszkowsky LS, Ryan DP et al (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:1898-1903
134. Sun W, Haller DG, Mykulowycz K et al (2007) Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. Pro Am Soc Clin Oncol: abstract 4574
135. Gasparini G (2001) Metronomic scheduling: the future of chemotherapy. Lancet Oncol 2:733-740
136. Emmenegger U, Man S, Shaked Y et al (2004) A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 64: 3994-4000
137. Hsu CH, Yang TS, Hsu C et al (2007) Modified-dose capecitabine+bevacizumab for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): a phase II, single-arm study. Proc Am Soc Clin Oncol: abstract 15190
138. Jeong W, Chun HG, Cer D et al (2006) A combination of capecitabine and thalidomide in patients with hepatocellular carcinoma. Proc Am Soc Clin Oncol 24: abstract 4142
139. Qin LX, Tang ZY (2004) Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 130:497-513
140. Korn EL, Arbuck SG, Pluda JM et al (2001) Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 19:265-272
141. Johnson JR, Williams G, Pazdur R (2003) End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404-1411
142. Stadler WM (2006) New targets, therapies, and toxicities: lessons to be learned. J Clin Oncol 24:4-5
143. Roberts TG Jr, Lynch TJ Jr, Chabner BA (2003) The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. J Clin Oncol 21:3683-3695
144. Center for Drug Evaluation and Research, FDA (2003) Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. Accessed on Feb 13, 2007 at URL: http://www.fda.gov/cder/guidance/
145. Weinshilboum R (2003) Inheritance and drug response. N Engl J Med 348:529-537
146. Llovet JM, Bruix J (2003) Systemic review of randomized trials for unresectable hepatoceldlular carcinoma: chemoembolization improves survival. Hepatology 37:429-442
147. Barbare JC, Bouche O, Bonnetain F et al (2005) Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 23:4338-4346
148. Becker G, Allgaier HP, Olschewski M et al (2007) Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 45:9-15
149. Yuen MF, Poon RT, Lai CL et al (2002) A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 36:687-691
150. Chow PK, Tai BC, Tan CK et al (2002) High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 36:1221-1226